Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer

Current Oncology

Volumn 18, Issue SUPPL. 2, 2011, Pages

  Gill, S ^a   Berry, S ^b   Biagi, J ^c   Butts, C ^d   Buyse, M ^e   Chen, E ^f   Jonker, D ^g   Marginean C ^h   Samson, B ⁱ   Stewart, J ^f   Thirlwell, M ^j   Wong, R ^k   Maroun, J A ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e HASSELT UNIVERSITY   (Belgium)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g OTTAWA REGIONAL CANCER CENTRE   (Canada)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁱ HÔPITAL CHARLES LEMOYNE   (Canada)

^j MONTREAL GENERAL HOSPITAL   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

Metastatic colorectal cancer; Progression free survival; Randomized clinical trials; Surrogate endpoints; Targeted therapies

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COLORECTAL CANCER; DOSE RESPONSE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; METASTASIS; METASTASIS RESECTION; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 80053467288     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i0.958     Document Type: Article

References (43)

1. Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005.
2. Rothbarth J, van de Velde CJ. Treatment of liver metastases of colorectal cancer. Ann Oncol 2005;16(suppl 2):ii144-9.
3. Paschos KA, Bird N. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. Hippokratia 2008;12:132-8.
4. McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol 2007;16:3-5.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
10. Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase iii trials in colorectal and breast cancer. J Clin Oncol 2003;21:2045-7.
11. Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007;25:5153-4.
12. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
13. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167-78.
14. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000;1:49-67.
15. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24.
16. Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006;5:173-86.
17. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562-8.
18. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-8.
19. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
20. Tournigand C, André T, Achille E, et al. folfiri followed by folfox6 or the reverse sequence in advanced colorectal cancer: a randomized gercor study. J Clin Oncol 2004;22:229-37.
21. Tournigand C, Cervantes A, Figer A, et al. optimox1: a randomized study of folfox4 or folfox7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a gercor study. J Clin Oncol 2006;24:394-400.
22. Falcone A, Ricci S, Brunetti I, et al. Phase iii trial of infusional fluorouracil, leucovorin, oxiliplatin, and irinotecan (folfoxiri) compared with infusional fluorouracil, leucovorin, and irinotecan (folfiri) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6.
23. Nordlinger B, Sorbye H, Glimelius B, et al. on behalf of the eortc Gastro-Intestinal Tract Cancer Group; Cancer Research U.K.; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie; Australasian Gastro-Intestinal Trials Group; and Fédération Francophone de Cancérologie Digestive. Perioperative chemotherapy with folfox4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (eortc Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007-16.
24. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase iii study. J Clin Oncol 2008;26:2013-9.
25. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase iii study Errata in: J Clin Oncol 2009;27:653
26. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase iii study J Clin Oncol 2008;26:3110
27. Cunningham D, Sirohi B, Pluzanska A, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009;20:244-50.
28. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase iiib trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
29. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
30. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
31. Fischer von Weikersthal L, Schalhorn A, Stauch M, et al. Phase iii trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011;47:206-14.
32. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase iii max study. J Clin Oncol 2010;28:3191-8.
33. U.S. Department of Health and Human Services, Food and Drug Administration (fda), Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: fda; 2005. [Available online at: http://www.bcg-usa.com/regulatory/docs/2005/FDA20054B.pdf; cited February 21, 2011]
34. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
35. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised recist guideline (version 1.1). Eur J Cancer 2009;45:228-47.
36. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase iii clinical trials: important design element or unnecessary expense? J Clin Oncol 2008;26:3791-6.
37. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12.
38. Allegra C, Blanke C, Buyse M, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007;25:3572-5.
39. Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007;25:2122-6.
40. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-32.
41. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol 2009;27:5958-64.
42. Michaelis LC, Ratain MJ. Measuring response in a post-recist world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409-14.
43. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-84.